Synthesis and Biological Assessment of Chalcone and Pyrazoline Derivatives as Novel Inhibitor for ELF3-MED23 Interaction

Reviewer #1 (Public Review):

Summary:

Soo-Yeon Hwang et al. synthesized and characterized a new set of small molecules targeting the interaction between ELF3-MED23, the transcription factor, and a coactivator for HER2 transcription, respectively. The authors used a combination of biochemical analysis, cell-based assays, and an in vivo xenograft model to prove that the lead compound 10 inhibits the HER2 transcription and protein expression levels, subsequently inducing anticancer activity in the gastric cancer cell line, the xenograft model, particularly in the trastuzumab-resistant cell line. The experiential data is solid and supports the model for the anticancer potency of the compound for the HER2+ gastric cancer model. Although the compound showed promising data for its potential antitumor activity for HER2+ cancers, it is a little bit narrow to the HER2+ cancer field since the most relevant HER2+ cancer model is HER2+ breast cancer and the Herceptin-resistance, indeed the author also discussed this point in the manuscript. Therefore, additional data with the breast cancer HER2+ cell model will help to impact the work in the field.

Strengths:

The current manuscript proposed a potential alternative strategy targeting HER2 overexpression cancers by attenuating HER2 transcription levels. The study provides solid evidence that the lead compound 10 can interrupt the binding of ELF3 to MED23, leading to the inhibition of HER2 transcription. Remarkably, the following cell-based assays and xenograft model revealed the promising antitumor activity of the compound in the gastric cancer model.

Weaknesses:

While the novel compound showed a promising potency to the HER2-positive gastric cancer cells and xenograft model, it would be great to also to be evaluated with the HER2-positive breast cancer cell models. The author did not compare the current compounds with other therapeutic strategies targeting HER2 expression at the genetic level. It is unclear whether the EGFR inhibitors gefitinib and canertinib but not HER2-specific inhibitors (i.e. tucatinib) were used as a control in the manuscript.

Reviewer #2 (Public Review):

Summary:

The findings highlight the importance of targeting the ELF3-MED23 protein-protein interaction (PPI) as a potential therapeutic strategy for HER2-overexpressing cancers, notably gastric cancers, as an alternative to trastuzumab. The evidence, including the strong potency of compound 10 in inhibiting ELF3-MED23 PPI, its capacity to lower HER2 levels, induce apoptosis, and impede proliferation both in laboratory settings and animal models, indicates that compound 10 holds promise as a novel therapeutic option, even for cases resistant to trastuzumab treatment.

Strengths:

The experiments conducted are robust and diverse enough to address the hypothesis posed.

Weaknesses:

The rationale behind the proposed structural modifications for the three groups of compounds is not clear.

Reviewer #3 (Public Review):

Summary:

The authors synthesized a compound which can inhibit ELF3 and MED23 interaction which leads to inhibition of HER2 expression in gastric cancer.

Strengths:

Enough evidence shows the potency of compound 10 in inhibiting ELF3 and MED23 interaction.

Weaknesses:

Compound 10 potency as PPI inhibitor has been shown in only one cell line NCI-N87.